AstraZeneca Plc (AZN.L) Announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to
reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and
established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The approval is
based on results from the landmark DECLARE-TIMI 58 CV outcomes trial (CVOT), the largest sodiumglucose cotransporter 2 (SGLT2) inhibitor CVOT conducted to date to evaluate T2D patients with
multiple CV risk factors or established CV disease.